"If Dr. Missling keeps to his announced schedule, there will be two significant data releases in the next 11 trading days, and if the data is as good as intimated, it will be detailed and very supportive of two drug candidates. IMO, the market is still ignoring the obvious that Dr. Missling is about to release the Kraken and the opportunity today is huge to grab some stock before it is much higher. Just saying, do your due diligence and weigh the risk/ reward." - by End2War on Yahoo Finance
The following are the catalysts for AVXL, likely to happen before Jul. 2021 __________________________________________________________
1. Complete data ANAVEX®2-73 U.S. Rett syndrome Phase 2 study –expected Q2 2021
2. Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study –expected Q2 2021
3. Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial –expected mid 2021
4. Top-line data Phase 1 ANAVEX®3-71 clinical trial –expected mid 2021
__________________________________________________________
BTW, C Wainwright & Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and raises the price target from $17 to $25.
